Therefore, DAC, which has already been approved by the FDA for the treatment of myelodysplastic syndromes, could be used in combination with 4-OHT to cure ER-positive breast tumors and prevent ERα36-dependent acquired resistance to treatment. Here, ESR1 is linked to breast neoplasm.